Grace Therapeutics Clears FDA Hurdle for GTx-104 Resubmission
Event summary
- Grace Therapeutics received FDA Type A meeting minutes confirming no clinical safety or efficacy deficiencies for GTx-104.
- FDA's Complete Response Letter (CRL) cited manufacturing compliance issues, not product-specific quality findings.
- Company is pursuing a dual-source manufacturing strategy, adding a U.S.-based site to reduce reliance on a single source.
- GTx-104 showed a 19% reduction in clinically significant hypotension compared to oral nimodipine in the STRIVE-ON trial.
The big picture
Grace Therapeutics' clearance of regulatory hurdles for GTx-104 comes amid increasing scrutiny on manufacturing compliance in the biopharma sector. The company's strategic pivot to a dual-source manufacturing approach reflects broader industry trends toward risk mitigation in drug development pipelines. With GTx-104 targeting a significant unmet need in aneurysmal subarachnoid hemorrhage (aSAH) patients, successful navigation of these regulatory and operational challenges could position Grace Therapeutics as a key player in neurocritical care therapeutics.
What we're watching
- Regulatory Pathway
- Whether Grace Therapeutics can successfully address all CRL items and secure NDA resubmission approval.
- Manufacturing Risk
- The pace at which the company's current contract manufacturer can remediate cGMP issues and pass FDA reinspection.
- Execution Dynamics
- How the dual-source manufacturing strategy will impact timelines and costs for GTx-104's commercialization.